Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
B7-H3 siRNA
- Development stage
- Preclinical
- Lead developer
- Institute for Cancer Research, Oslo
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intravenous
01
Overview
B7-H3 siRNA (also known as CD276 siRNA) is a research-stage RNA interference (RNAi) agent designed to silence the expression of B7-H3, a transmembrane protein and member of the B7 family of immune regulators. B7-H3 is frequently overexpressed in various malignancies, including breast cancer and melanoma, where it contributes to tumor cell proliferation, invasion, and resistance to chemotherapy. Research presented at AACR 2016 demonstrated that knockdown of B7-H3 using siRNA reduces the glycolytic capacity of tumor cells and increases their sensitivity to both traditional anti-cancer agents and targeted inhibitors of the PI3K/AKT/mTOR and MAPK pathways. This suggests that B7-H3 plays a critical role in metabolic reprogramming and therapeutic resistance, making its suppression a potential strategy for enhancing the efficacy of existing cancer treatments.
- Other names
- B7-H3 knockdownB-7-H3 knockdownB 7-H3 knockdownCD276 siRNACD-276 siRNACD 276 siRNAB7-H3 siRNA/knockdown
02
Targets
B7-H3
Beyond the preview
Go deeper on B7-H3 siRNA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on B7-H3 siRNA.